Analysis of the pharmacokinetic boosting effects of ritonavir on oral bioavailability of drugs in mice

Drug Metabolism and Pharmacokinetics

Volumn 28, Issue 2, 2013, Pages 144-152

  Tomaru, Atsuko ^a   Takeda Morishita, Mariko ^a,b   Banba, Hirokazu ^a   Takayama, Kozo ^a  

^a HOSHI UNIVERSITY   (Japan)

^b KOBE GAKUIN UNIVERSITY   (Japan)

Author keywords

CYP3A; Drug drug interactions; Oral bioavailability; P gp; Ritonavir

Indexed keywords

CYTOCHROME P450 3A; DORMICUM INJECTION; FEXOFENADINE; ISOENZYME; ITRACONAZOLE; MIDAZOLAM; PRAVASTATIN; RITONAVIR; SAQUINAVIR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG TRANSPORT; ENZYME INHIBITION; FEMALE; FIRST PASS EFFECT; IN VITRO STUDY; LIVER; MOUSE; NONHUMAN; PREDICTION; SMALL INTESTINE;

EID: 84876762993     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.DMPK-12-RG-057     Document Type: Article

References (40)

1. Kempf, D. J., Marsh, K. C., Kumar, G., Rodrigues, A. D., Denissen, J. F., Mcdonald, E., Kukulka, M. J., Hsu, A., Granneman, G. R., Baroldi, P. A., Sun, E., Pizzuti, D., Plattner, J. J., Norbeck, D. W. and Leonard, J. M.: Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob. Agents Chemother., 41: 654-660 (1997).
2. Kumar, G. N., Rodrigues, A. D., Buko, A. M. and Denissen, J. F.: Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J. Pharmacol. Exp. Ther., 277: 423-431 (1996).
3. Lin, J. H.: Human immunodeficiency virus protease inhibitors from drug design to clinical studies. Adv. Drug Deliv. Rev., 27: 215-233 (1997).
4. Youle, M.: Overview of boosted protease inhibitors in treatmentexperienced HIV-infected patients. J. Antimicrob. Chemother., 60: 1195-1205 (2007).
5. Choo, E. F., Leake, B., Wandel, C., Imamura, H., Wood, A. J. J., Wilkinson, G. R. and Kim, R. B.: Pharmacological inhibition of Pglycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab. Dispos., 28: 655-660 (2000).
6. Kumar, S., Kwei, G. Y., Poon, G. K., Iliff, S. A., Wang, Y., Chen, Q., Franklin, R. B., Didolkar, V., Wang, R. W., Yamazaki, M., Chiu, S. L., Lin, J. H., Pearson, P. G. and Baillie, T. A.: Pharmacokinetics and interactions of a novel antagonist of chemokine receptor 5 (CCR5) with ritonavir in rats and monkeys: role of CYP3A and P-glycoprotein. J. Pharmacol. Exp. Ther., 304: 1161-1171 (2003).
7. Perloff, M. D., von Moltke, L. L. and Greenblatt, D. J.: Fexofenadine transport in Caco-2 cells: inhibition with verapamil and ritonavir. J. Clin. Pharmacol., 42: 1269-1274 (2002).
8. Gupta, A., Zhang, Y., Unadkat, J. D. and Mao, Q.: HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2). J. Pharmacol. Exp. Ther., 310: 334-341 (2004).
9. Ye, Z. W., Camus, S., Augustijns, P. and Annaert, P.: Interaction of eight HIV protease inhibitors with the canalicular efflux transporter ABCC2 (MRP2) in sandwich-cultured rat and human hepatocytes. Biopharm. Drug Dispos., 31: 178-188 (2010).
10. Annaert, P., Ye, Z. W., Stieger, B. and Augustijns, P.: Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1. Xenobiotica, 40: 163-176 (2010).
11. Chan, L. M. S., Lowes, S. and Hirst, B. H.: The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability. Eur. J. Pharm. Sci., 21: 25-51 (2004).
12. Kim, A. E., Dintaman, J. M., Waddell, D. S. and Silverman, J. A.: Saquinavir, an HIV protease inhibitor, is transported by P-glycoprotein. J. Pharmacol. Exp. Ther., 286: 1439-1445 (1998).
13. Kharasch, E. D., Bedynek, P. S., Walker, A., Whittington, D. and Hoffer, C.: Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: II. Ritonavir effects on CYP3A and P-glycoprotein activities. Clin. Pharmacol. Ther., 84: 506-512 (2008).
14. Huisman, M. T., Smit, J. W., Wiltshire, H. R., Hoetelmans, R. M. W., Beijnen, J. H. and Schinkel, A. H.: P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir. Mol. Pharmacol., 59: 806-813 (2001).
15. Washington, C. B., Wiltshire, H. R., Man, M., Moy, T., Harris, S. R., Worth, E., Weigl, P., Liang, Z., Hall, D., Marriott, L. and Blaschke, T. F.: The disposition of saquinavir in normal and P-glycoprotein deficient mice, rats, and in cultured cells. Drug Metab. Dispos., 28: 1058-1062 (2000).
16. Richter, M., Gyémánt, N., Molnár, J. and Hilgeroth, A.: Comparative effects on intestinal absorption in situ by P-glycoprotein-modifying HIV protease inhibitors. Pharm. Res., 21: 1862-1866 (2004).
17. Hartkoorn, R. C., Kwan, W. S., Shallcross, V., Chaikan, A., Liptrott, N., Egan, D., Sora, E. S., James, C. E., Gibbons, S., Bray, P. G., Back, D. J., Khoo, S. H. and Owen, A.: HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms. Pharmacogenet. Genomics, 20: 112-120 (2010).
18. Shitara, Y., Hirano, M., Sato, H. and Sugiyama, Y.: Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/ OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J. Pharmacol. Exp. Ther., 311: 228-236 (2004).
19. Yamano, K., Yamamoto, K., Kotaki, H., Sawada, Y. and Iga, T.: Quantitative prediction of metabolic inhibition of midazolam by itraconazole and ketoconazole in rats: implication of concentrative uptake of inhibitors into liver. Drug Metab. Dispos., 27: 395-402 (1999).
20. Emoto, C., Yamazaki, H., Yamasaki, S., Shimada, N., Nakajima, M. and Yokoi, T.: Characterization of cytochrome P450 enzymes involved in drug oxidations in mouse intestinal microsomes. Xenobiotica, 30: 943-953 (2000).
21. Interview form of Saquinavir. http://chugai-pharm.jp/hc/ss/pr/drug/inv_cap0200/if/index.html. Accessed 22 July (2012).
22. Davies, B. and Morris, T.: Physiological parameters in laboratory animals and humans. Pharm. Res., 10: 1093-1095 (1993).
23. Ito, K., Iwatsubo, T., Kanamitsu, S., Ueda, K., Suzuki, H. and Sugiyama, Y.: Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. Pharmacol. Rev., 50: 387-412 (1998).
24. Kilby, J. M., Sfakianos, G., Gizzi, N., Siemon-Hryczyk, P., Ehrensing, E., Oo, C., Buss, N. and Saag, M. S.: Safety and pharmacokinetics of oncedaily regimens of soft-gel capsule saquinavir plus minidose ritonavir in human immunodeficiency virus-negative adults. Antimicrob. Agents Chemother., 44: 2672-2678 (2000).
25. Plosker, G. L. and Scott, L. J.: Saquinavir. A review of its use in boosted regimens for treating HIV infection. Drugs, 63: 1299-1324 (2003).
26. Komura, H. and Iwaki, M.: Species differences in in vitro and in vivo small intestinal metabolism of CYP3A substrates. J. Pharm. Sci., 97: 1775-1800 (2008).
27. Perloff, M. D., von Moltke, L. L., Court, M. H., Kotegawa, T., Shader, R. I. and Greenblatt, D. J.: Midazolam and triazolam biotransformation in mouse and human liver microsomes: relative contribution of CYP3A and CYP2C isoforms. J. Pharmacol. Exp. Ther., 292: 618-628 (2000).
28. van Waterschoot, R. A. B., van Herwaarden, A. E., Lagas, J. S., Sparidans, R. W., Wagenaar, E., van der Kruijssen, C. M. M., Goldstein, J. A., Zeldin, D. C., Beijnen, J. H. and Schinkel, A. H.: Midazolam metabolism in cytochrome P450 3A knockout mice can be attributed to up-regulated CYP2C enzymes. Mol. Pharmacol., 73: 1029-1036 (2008).
29. Tachibana, T., Kato, M., Watanabe, T., Mitsui, T. and Sugiyama, Y.: Method for predicting the risk of drug-drug interactions involving inhibition of intestinal CYP3A4 and P-glycoprotein. Xenobiotica, 39: 430-443 (2009).
30. Gotoh, Y., Kamada, N. and Momose, D.: The advantages of the using chamber in drug absorption studies. J. Biomol. Screen., 10: 517-523 (2005).
31. Tahara, H., Kusuhara, H., Fuse, E. and Sugiyama, Y.: P-glycoprotein plays a major role in the efflux of fexofenadine in the small intestine and blood-brain barrier, but only a limited role in its biliary excretion. Drug Metab. Dispos., 33: 963-968 (2005).
32. Matsushima, S., Maeda, K., Hayashi, H., Debori, Y., Schinkel, A. H., Schuetz, J. D., Kusuhara, H. and Sugiyama, Y.: Involvement of multiple efflux transporters in hepatic disposition of fexofenadine. Mol. Pharmacol., 73: 1474-1483 (2008).
33. Tian, X., Zamek-Gliszczynski, M. J., Li, J., Bridges, A. S., Nezasa, K., Patel, N. J., Raub, T. J. and Brouwer, K. L. R.: Multidrug resistanceassociated protein 2 is primarily responsible for the biliary excretion of fexofenadine in mice. Drug Metab. Dispos., 36: 61-64 (2008).
34. Ming, X., Knight, B. M. and Thakker, D. R.: Vectorial transport of fexofenadine across Caco-2 cells: involvement of apical uptake and basolateral efflux transporters. Mol. Pharm., 8: 1677-1686 (2011).
35. Akamine, Y., Miura, M., Sunagawa, S., Kagaya, H., Yasui-Furukori, N. and Uno, T.: Influence of drug-transporter polymorphisms on the pharmacokinetics of fexofenadine enantiomers. Xenobiotica, 40: 782-789 (2010).
36. Kiser, J. J., Gerber, J. G., Predhomme, J. A., Wolfe, P., Flynn, D. M. and Hoody, D. W.: Drug/drug interaction between lopinavir/ritonavir and rosuvastatin in healthy volunteers. J. Acquir. Immune Defic. Syndr., 47: 570-578 (2008).
37. Yoo, S. D., Kang, E., Shin, B. S., Jun, H., Lee, S., Lee, K. C. and Lee, K.: Interspecies comparison of the oral absorption of itraconazole in laboratory animals. Arch. Pharm. Res., 25: 387-391 (2002).
38. Product monograph of Itraconazole. http://www.janssen.ca/product/188. Accessed 22 July (2012).
39. Denissen, J. F., Grabowski, B. A., Johnson, M. K., Buko, A. M., Kempf, D. J., Thomas, S. B. and Surber, B. W.: Metabolism and disposition of the HIV-1 protease inhibitor ritonavir (ABT-538) in rats, dogs, and humans. Drug Metab. Dispos., 25: 489-501 (1997).
40. Lledó-García, R., Nácher, A., Prats-García, L., Casabó, V. G. and Merinosanjuán, M.: Bioavailability and pharmacokinetic model for ritonavir in the rat. J. Pharm. Sci., 96: 633-643 (2007).